Navigation Links
PDL BioPharma Announces Second Quarter 2012 Financial Results
Date:8/2/2012

INCLINE VILLAGE, Nev., Aug. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Royalty revenues for the second quarter of 2012 increased three percent to $125.9 million from $122.1 million reported in the second quarter of 2011. For the first six months of 2012, royalty revenues increased four percent to $203.2 million from $195.5 million reported in the comparable period of 2011. Total revenue for the first six months of 2012 of $203.2 million is one percent lower than total revenue for the first six months of 2011 of $205.5 million, as a result of a one-time settlement payment of $10 million from UCB Pharma received in 2011.

Royalty revenues for the second quarter of 2012 are based on first quarter 2012 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from first quarter 2012 sales of Herceptin®, which is marketed by Genentech and Roche, Lucentis® and Xolair®, which are marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the second quarter is net of payments made under PDL's February 2011 settlement agreement with Novartis Pharma AG.

General and administrative expenses for the second quarter of 2012 were $5.1 million, compared with $3.8 million in the same quarter of 2011. For the six months ended June 30, 2012, general and administrative expenses were $12.1 million compared to $9.6 million in the comparable period of 2011. The increase in expenses for both the quarter and six months ended June 30, 2012, is primarily due to expense
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
2. Global Biopharmaceuticals Market 2011-2015
3. PDL BioPharma to Announce Second Quarter 2012 Financial Results on August 2, 2012
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
6. ePharmaSolutions To Acquire Global Patient Recruitment Firm Polaris BioPharma
7. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
8. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
9. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Genesis Biopharma Issues Letter To Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The American Brain Tumor Association ... its Discovery Research Grant program. LOIs are due no ... CDT. Discovery Grants are one-year, $50,000 grants ... to change current diagnostic or treatment paradigms for adults ... novel research at its earliest stages, in the hopes ...
(Date:9/1/2015)... , Sept. 1, 2015 ... cancer death in American men. One in ... and 233,000 new cases are diagnosed annually. That ... are using a powerful new technique, MRI Fusion ... and large cancer lesions, treating only the affected ...
(Date:9/1/2015)... Eau Claire, WI (PRWEB) , ... September 01, 2015 , ... ... 2015), Alexi Venice expertly transports the reader to a not-so-distant future faced with an ... McCallan, a beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma ... Equine cervical facet joint problems can be caused by injuries and abnormalities of ... of nerve roots or of the spinal cord itself. This can manifest itself ...
Breaking Biology Technology:American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... intense scrutiny that started in September when Vioxxs manufacturer ... concerns, the U.S. Food and Drug Administration and the ... the biggest challenges has been the pipeline problem, the ... innovative medical therapies reaching patients. In its March ...
... Americans, Canada is the 51st state to the north. ... not information technology. , ,In fact, Vancouver, British Columbia ... enough to spend the better part of a week there ... few weeks, I'll fill you in on some of the ...
... large managed medical provider network based in Milwaukee is ... Physicians Network, Inc. (IPN), one of the largest managed ... member physicians, and MedcomSoft Inc. announced today a pilot ... of the pilot project can acquire MedcomSoft Record. , ...
Cached Biology Technology:Challenging times for FDA and drug companies equals IT opportunities 2Challenging times for FDA and drug companies equals IT opportunities 3Imagis emerges from bumpy road 2Imagis emerges from bumpy road 3
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Network, Departmental and Workgroup Scanners Recognized by ... the Leading Guide ... 2 /PRNewswire/- Fujitsu Computer Products of,America, Inc., a market ... seven Fujitsu scanners earned the "Editor,s Choice",designation in the ...
... reports documenting the therapeutic efficacy of short interfering RNAs ... be describing non-specific therapeutic effects related to the ability ... a paper in the September 2008 issue (Volume 19, ... peer-reviewed journal published by Mary Ann Liebert, Inc. The ...
... of General Psychiatry, researchers at the Johns Hopkins University ... molecular circuitry associated with schizophrenia that links three previously ... exciting because until now the many known genetic factors ... way," says Akira Sawa, M.D., Ph.D., director of the ...
Cached Biology News:Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Hopkins researchers piece together gene 'network' linked to schizophrenia 2Hopkins researchers piece together gene 'network' linked to schizophrenia 3
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Biology Products: